Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ot. No, dc, it was not Baletwine World Headquarters. I paid that willingly. Thanks for changing my entry to GENT.
And seriously, good luck on your "something similar".
Thanks ico on the gapper pick:) I make it look very lucky. GENT was just a roll of the dice without even having read the news.
Got up this morning to see some fraudulent activity on my PayPal account. Someone apparently acquired my password. Fortunately I think it will be resolved and my credit card does not seem to be in jeopardy.
PayPal was very helpful and professional.
ot: Thanks bale. It is coming back to me slowly. I failed in my first effort and edited it out. with your help it will work next time.
Life is GREAT!! Thanks and the same sentiments back to you.
Gapper GENT Don't know anything about it but I have to leave and don't have time to look further. A very strong move today on huge volume.
Tanker POZN A bright future but it might need a rest.
Jeez, lI can't believe that I have forgotten how to post a chart. I'll figure it out later.
re SLXP fwiw
January 5, 2010 7:05 AM EST
Piper Jaffray maintains an Overweight rating on Salix Pharmaceuticals (Nasdaq: SLXP), raises price target from $29 to $58.
Piper analyst says, "We are highlighting Salix as our top small-cap specialty pharma pick in 2010. We believe that Street estimates (including ours) have been significantly underestimating the pricing power associated with Xifaxan in its expansion markets. We are raising our Xifaxan estimates to better reflect pricing expectations cited by SLXP at its analyst day in November 2009. We remain confident that Xifaxan, with label expansions on the way in hepatic encephalopathy (HE) and non-constipation irritable bowel syndrome (IBS), will emerge as a blockbuster product and would continue to be enthusiastic buyers of SLXP shares...Raising Xifaxan sales estimates; over $1B in sales by 2014. Our EPS estimate rises to $7.55 by 2014, up from $3.42. With a relatively concentrated GI prescriber audience, and therefore modest sales force expansion requirements, we believe that margin expansion over the long-term could be compelling. SLXP has suggested that it can reach 70% of the IBS prescriber audience (plus the entire HE audience) with a sales force of 400 reps (it is already expanding its sales organization to 240 reps)...With Xifaxan peak sales in excess of $1.0B realistic, we believe Salix is the most compelling small-cap growth story in the specialty pharma space."
To see all the upgrades/downgrades on shares of SLXP, visit our Analyst Ratings page.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focuses on acquiring, developing and commercializing prescription drugs used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract.
ot. Thanks. That's the goal.
Thanks dc. I might try again tomorrow. I'm out of here today in my quest to be 1/2 as good as you:)
Tanker APPA 1.15 See the referenced post.
Hey Sulph!! Jerry's golf glove shoes in purple, of course. What a dumb question:))))
Thank you ico and tuna. Nice to be here:)
Happy to see that you are trading again fish. I have some CREG too. Thanks for posting the DD.
I'm finally 99% retired and loving it.
Gapper CREG
CREG)China Recycling Energy Corp. Announces Listing on NASDAQ Capital Market
PPS:$5.55
Come Monday this company exposure will rise!
XI'AN, China, March 19 /PRNewswire-Asia-FirstCall/ -- China Recycling Energy Corp. (OTC Bulletin Board: CREG; "CREG" or "the Company"), a leading industrial waste-to-energy solution provider in China, today announced that the Company's common stock will be listed on the NASDAQ Global Market and begin trading on Monday, March 22, 2010. The Company's sticker symbol will remain "CREG".
Mr. Guohua Ku, Chairman and CEO of CREG, commented, "By completing the listing with NASDAQ, we have reached a significant milestone in our Company's history. On behalf of the entire CREG organization, I want to thank everyone involved in making the listing on NASDAQ a reality. We are honored that the listing committee has approved our application, recognized our commitment to growth and believes in the strength and future of CREG." Mr. Ku concluded, "We expect the new listing on NASDAQ will provide greater exposure and opportunities for CREG and its shareholders."
About NASDAQ OMX
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with approximately 3,700 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX First North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com . *Please follow NASDAQ OMX on Facebook ( http://www.facebook.com/pages/NASDAQ-OMX/108167527653 ) and Twitter ( http://www.twitter.com/nasdaqomx ).
About China Recycling Energy Corp.
China Recycling Energy Corp. (OTCBB:CREG.OB;.ob - News) is based in Xi'an, China and provides environmentally friendly waste-to-energy technologies to recycle industrial byproducts for steel mills, cement factories and coke plants in China. Byproducts include heat, steam, pressure, and exhaust to generate large amounts of lower-cost electricity and reduce the need for outside electrical sources. The Chinese government has adopted policies to encourage the use of recycling technologies to optimize resource allocation and reduce pollution. Currently, recycled energy represents only an estimated 1% of total energy consumption and this renewable energy resource is viewed as a growth market due to intensified environmental concerns and rising energy costs as the Chinese economy continues to expand. The management and engineering teams have over 20 years of experience in industrial energy recovery in China.
For more information about CREG, please visit http://www.creg-cn.com .
http://finance.yahoo.com/news/China-Recycling-Energy-Corp-prnews-1482560944.html?x=0&.v=8
Re the rereading of the Stanly PR from July. A good idea Salty. I will reread the entire Ibox. Haven't done so in several months.
Thanks rookinvestor, Salty Pepper and ERoche
Re revenues: They received a task order from Honeywell in December. Amount unknown but probably 5.8M or much less. If they received cash from that order in December it will show in their revenues. If not, it will show in this quarter.
I'm open to correction if someone finds this post inaccurate.
I hope it reacts favorably to this Walgreens news. So far, it looks like the news is being treated as having already been factored in.
On the other hand, it could stop what might have been a deeper correction.
Either way it does not matter. This stock likely has an extremely bright future. Walmart is probable in June. Barring the unforeseen, (which can always happen), XCHO will go much higher.
Over-the-Counter (OTC) Pain Reliever, Cobroxin, to be Sold in Walgreens
XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation’s largest pharmacy chains with 7,162 drugstores located throughout the United States.
“As one of the largest and most well recognized pharmacy chains in North America, we are pleased that Walgreens has chosen to offer Cobroxin for sale in its drugstores throughout the United States,” commented Frank Rizzo, President and CEO of XenaCare Holdings. “We look forward to working closely with Walgreens as we prepare for this launch and finalize our promotional strategy to support ongoing sales efforts by the retailer,” he added.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
* All Natural
* Non-Addictive
* Non-Narcotic
* Non-Opiate
* Long Lasting
XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB:NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.
http://www.XenaCareHoldings.com
http://www.Cobroxin.com
Cautionary Note Concerning Forward Looking Statements
Except for the historical and present factual information contained herein, the matters set forth in this document, including statements regarding our plans for specific advertising and marketing campaigns supporting Cobroxin are forward looking statement and subject to change. Investors are cautioned that these forward-looking statements are not guarantees of future performance. Actual events or results may differ from the Company’s current plans. There are many risks, uncertainties and other factors that can prevent the achievement of our goals or cause results to differ from those expressed or implied by these forward-looking statements including, without limitation, the risks described in greater detail in filings made by the Company with the Securities and Exchange Commission. The Company assumes no obligation to publicly update or revise its forward-looking statements even if experience or future events make it clear that any of the anticipated results expressed or implied herein will not be realized. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.
Bookmark With :
Facebook MySpace Twitter Digg Del.icio.us StumbleUpon Reddit Google Bookmarks Newsvine Technorati Furl AIM Slashdot Yahoo
Historical Chart Intraday Chart
Wallgreens on May 1. News viaSchwab's Streetsmart Pro
Wallgreens on May 1 New vis Schwabs Streetsmart Pro
EVRM is now at 0.0099. Up 30% om 3M shares
Some great posts. Mr Brown. You are what every moderator should be.
Many, many thanks to you.
re NPHC and XCHO Probart. I agree. These are the only two stocks that I own that are being treated as investments. I think the odds favor both being multi-dollar values within two years.
My wife and I thank you Sheff for XCHO. I purchased it, after some quick DD, about 10 minutes after your initial post.
I have held XCHO for only a couple of months after having traded it earlier.
"Never bet more than you can afford to lose."
I have been wrong many times. Right many times also:)
Bingo crngreen. Thanks:)
Correct me if I'm wrong but I have been under the impression that they are selling to individuals in the rest of the world.
Hope I'm not inaccurate. On the other hand, I hope I am wrong. I would love to have all the sales to XCHO.
The high is 0.43 and it is looking like it might bo today. We shall see.
re revenues: My guess is that they sold some to XCHO at a wholesale price and sold some at retail to internet customers.
Nice analysis slbrown. Thank you. Everything you said makes sense and it does help. I have a great deal of stock experience but I'm a neophyte when it comes to pinks in the healthcare sector. It is a pleasure to be able to talk with someone who has experience in the field
I do have shares in both and will likely be adding this week. Besides enjoying having the positions I am also excited about the product(s).
OOPS! Guess I'm not yet awake. The referenced msg should read NPHC and I should have been clearer and stated that I have twice as much money in XCHO.
I am guessing that XCHO will do better in the next six months and that NPHC might be the better buy longer term. Another opinion will be appreciated.
slbrown: What is you comparative take on NPHA and XCHO on a six month and 12-18 month basis. I currently have about twice as much XCHO.
Interested in hearing the viewpoint of someone I trust that has been in the business.
We are in good hand slbrown.
""I believe in posting the facts and being honest, regardless of what is uncovered in terms of NPHC and their operations as they move forward.""
I love that sentence. I've been doing this for about 16 years and lack of honesty and transparency, imo, have have lost people far more money than have negative observations.
I hate dishonest bashers, but even they are far less dangerous than are those that pump every transaction and cannot tolerate "negativity"
Your background is perfect for this board and for XCHO. I will continue to read all of your posts with trust and appreciation.
Thank you bigtime for your contribution.
Jerry
Not expecting it to happen but would love to see a hammer.
re The Bagdad Detainee contract. I don't think one can make the assumption that the contract has been renewed. Would we not have had an announcement before now?
That is the contract that produced the revenues reported in the 3rd qtr reports. I expected it to continue to produce going forward. That gives EVRM a minimum income level for 1 to 3 years.
It's going to take a lot more than this one contract to get us where we want to go.
Even so, having a steady source of income is a great thing, especially for a pinkie.
Investor 911: I'm not certain that this contract is not for an unspecified amount of a 22M contract for which Honeywell is the prime contractor. Big news either way. Your read please?
(Honeywell), a division of Honeywell International. Under a $22,426,474, indefinite-delivery/indefinite-quantity, cost-plus-fixed-fee, performance-based PRIME contract[, STS will provide engineering support to the Navy, Department of Defense (DoD), and other government agencies, including the Defense Logistics Agency (DLA). This development follows the Department of the Navy approval of STS's capabilities to accommodate The Space and Naval Warfare Systems Center (SPAWAR); this authorization required a technical review of STS conducted by Department of Defense
LOLOL Now that is the best reasoning I've heard. I might add that it also has a base of substance.
The best to your health:)
Let me explain my rationale before you tell me to chill again. Guessing ridiculous numbers creates expectations that cannot be met. Which in turn creates disappointments. Which creates selling, which creates a drop in pps which creates little red numbers on my ticker board, which creates big red numbers on my blood pressure meter, which creates a stroke which creates a trip to the hospital which creates a selloff of my shares of EVRM because I ain't got no money because my shares of EVRM are not worth a pint of beans.
Why, because you freakin posted a 160% gain in pps by EOY!
So be careful what you post you don't want all of that hanging over your head do you? ;)
re NPHC presentation tomorrow night. Thank you for correcting me Probart. My bad.
GCKO 0.038 A nice late rally after bottoming at 0.025 earlier today.
Up 20% from yesterday's close.
I'm a little surprised that NPHC and XCHO are so far under the radar with the presentation tonight.
12/10/09 9-10:30PM(EST) NPHC On-Line Presentation w/Rik Deitsch
Thanks for digging more on the share structure Sterling. Loud applause and kudos to you.
Imo this is huge financially. Also psychologically.
It erases the biggest of my worries and dims the rest of my concerns.
ot: Thanks Wonder Woman. It was fun to drop in but it is even more fun not to be working. It may change, but at age 77, I think I have finally successfully retired.
The golf scores are improving but I think I might need to fly or drive to Alabama and get some lessons. On the other hand, not even dc can get my scores into the seventies.
We are about to leave for a day trip to Mt Rainier. High eighties weather is predicted. It might be the last hot day in this calendar year.
My fondest thoughts go to you and to the board:) I will continue to drop in. Probably more frequently as the outdoor season comes to an end.
As for you, dear lady, you will still have to put up with my pm's:)
Jerry
“With populations exceeding 33 million people in Canada and over 830 million people throughout Europe, the combined size of the pain market in these countries potentially exceeds that of the United States,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. “As we move forward with the registration process in Canada and Europe, we also plan to continue seeking qualified licensing partners to market and distribute our pain reliever worldwide,”
I don't see it as likely. Maybe a possibility based on the above paragraph.
Gapper CHIP I don't really think it has a chance after this run but it is fascinating.
Average daily vol 60 thousand. Today's vol 16.6M and rising.
Float of 6M OS of 14,8M
A very happy management that holds 59% of the shares.
It was an $8 stock soon after it ipo'd in 2007
Where is that excitable bovine?